Indium-111-labeled A7
monoclonal antibodies using two spacer-containing chelates, succinimido-EGS-
DTPA (EGS-
DTPA: diester spacer) and maleimido-C10-Bz-EDTA (C10-Bz-
EDTA:
hydrocarbon spacer) were investigated in human LS180 colon
tumor bearing nude mice and were compared with two non-spacer chelates, cyclic
DTPA dianhydride (
cDTPAA) and
isothiocyanatobenzyl-EDTA (SCN-Bz-
EDTA). Compared with
immunoconjugates using non-spacer chelates,
immunoconjugates using spacer-containing chelates, especially C10-Bz-EDTA-A7 showed lower 111In activity in normal organs. The radioactivity in the liver for C10-Bz-EDTA-A7 decreased continuously till 96 hrs postinjection, however, this liver radioactivity for EGS-DTPA-A7 showed little change after 24 hrs. Moreover, in liver subcellular distribution study, EGS-DTPA-A7 showed a higher activity retention in mitochondrial fraction which contained lysosome, a place for metabolizing and storing of 111In labeled antibody, than that of C10-Bz-EDTA-A7. The C10-Bz-EDTA-A7 conjugate demonstrated more preferable
tumor-to-non
tumor contrast on the scintigrams than that found with other three
immunoconjugates. Up to 96 hrs postinjection,
tumor bearing nude mice injecting with
immunoconjugates using spacer-containing chelates excreted twice radioactivity from whole body than that excreted by using non-spacer chelates. Interestingly, different from other three chelates, C10-Bz-EDTA-A7 were mainly excreted via feces. We conclude that the decrease of radioactivity in normal tissues in the case of EGS-DTPA-A7 was duo to the rapid decrease of activity in the blood, while in the case of C10-Bz-EDTA-A7 it was due to the quickly excreted small metabolite through faces. 111In labeled C10-Bz-EDTA conjugate is superior, at least when conjugated with A7, to other three chelate conjugates used in this study.